MODERNA PATENTED KEY COVID SPIKE PROTEIN SEQUENCE IN 2016

A study published 21 February, 2022 in Frontiers in Virology claims to have discovered that a sequence of the virus' spike protein is a 100 per cent match to a modified patented by Moderna—in 2016.

The genetic sequence patented by Moderna—and now found to be part of the SARS-CoV-2's furin

cleavage site in the spike protein that gives the virus access into human cells—is a 19-nucleotide sequence of a human gene called MSH3, which is a DNA repair gene.

Nucleotides code for specific amino acids

.The MSH3 gene works with the part of the immune system responsible for combatting cancer

by repairing damaged cells.

This pathway has been identified as a potential target for new cancer treatments.

What are the chances of a naturally occurring virus having a rarely encountered furin cleavage

site that is genetically identical to an engineered and patented one?

As noted in the patent application, the gene sequence has been modified "for the production

of oncology-related proteins and peptides," ostensibly for use in cancer research.

What's so curious here is that the scientists of the Frontiers in Virology paper searched all viral and

bacterial databases looking for matches to the furin cleavage site patented by Moderna, and SARS-

CoV-2 is the only pathogen that has this sequence.

It's an absolute match—100 per cent identical.

According to the researchers, the chance that SARS-CoV-2 would have randomly acquired this furin cleavage site through natural evolution is 1 in 3 trillion.

They also noted that "Recombination in an intermediate host is an unlikely explanation." What's more, it's known that inserting a furin cleavage site on the spike protein of

a virus will make it more infectious.

(Source: GlobalResearch.ca, 7

March 2022, https://is.gd/ueObTC)